- Clinical Trials
- January 2024
- 90 Pages
Global
From €1903EUR$2,000USD£1,629GBP
- Report
- March 2018
- 220 Pages
Global
From €1779EUR$1,870USD£1,523GBP
€2093EUR$2,200USD£1,792GBP
- Report
- May 2024
- 136 Pages
From €6184EUR$6,499USD£5,295GBP
- Report
- August 2022
- 117 Pages
Global
From €4519EUR$4,750USD£3,870GBP
- Report
- May 2021
- 73 Pages
Global
From €3200EUR$3,603USD£2,836GBP
- Report
- March 2024
- 104 Pages
Global
From €3500EUR$3,941USD£3,102GBP
- Report
- February 2024
- 180 Pages
Global
From €5232EUR$5,499USD£4,480GBP
The GABA Receptor Agonist market is a subset of the Central Nervous System Drugs market. GABA Receptor Agonists are drugs that activate the GABA receptor, a type of neurotransmitter receptor found in the brain. These drugs are used to treat a variety of neurological disorders, including anxiety, insomnia, and epilepsy. GABA Receptor Agonists are typically administered orally, intravenously, or intramuscularly.
The GABA Receptor Agonist market is highly competitive, with a number of large pharmaceutical companies vying for market share. Companies in this market include Pfizer, GlaxoSmithKline, Merck, and Novartis. Additionally, there are a number of smaller companies that specialize in the development and manufacture of GABA Receptor Agonists. Show Less Read more
